Business
GE HealthCare reports third quarter 2025 financial results
Revenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa (EMEA) and the U.S. Organic orders
About this update from Ge Healthcare Technologies Inc.
[{"type":"text","content":"\n\nRevenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa (EMEA) and the U.S.\n\n\n\n\nOrganic orders growth was 6% with growth across all segments\n\n\n\n\nNet income margin was 8.7%; Adjusted earnings before interest and taxes (EBIT) margin* was 14.8%\n\n\n\n\nDiluted earnings per share (EPS) were $0.98; Adjusted EPS* was $1.07\n\n\n\n\nCash flow from operating activities was $593 million; Free cash flow* was $483 million\n\n\n\n\nExcluding tariff impacts, margin and EPS would have exceeded prior year\n\n\n\n\nRaises the lower end of full-year 2025 Adjusted EPS* guidance range and reaffirms all other metrics\n\n\n\n CHICAGO--(BUSINESS WIRE)--\nGE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2025.\n\n\nGE HealthCare President and CEO Peter Arduini said, “We delivered robust orders with growth across all segments in the third quarter. This was led by customer demand for our differentiated solutions and a healthy capital equipment environment. Revenue performance was driven by Imaging, Advanced Visualization Solutions, and Pharmaceutical Diagnostics, and was ahead of our expectations. We continue to see momentum with commercial execution, where our teams leverage our broad portfolio and services, creating sustainable revenue and strengthening customer relationships. As a result of our increased R&D investments, we are entering a new wave of innovation and, coupled with our focus on lean, we expect to accelerate top and bottom line growth.”\n\n\nThird quarter 2025 total company financial performance\n\n\n\nRevenues of $5.1 billion increased 6% reported and 4% on an Organic* basis year-over-year. Revenue growth was driven by strength in EMEA and the U.S.\n\n\n\nTotal company book-to-bill was 1.06 times. Total company orders increased 6% organically year-over-year.\n\n\n\nNet income attributable to GE HealthCare was $446 million versus $470 million for the prior year, and Adjusted EBIT* was $761 million versus $795 million.\n\n\n\nNet income margin was 8.7% versus 9.7% for the prior year, down 100 basis points (bps). Adjusted EBIT margin* was 14.8% versus 16.3%, down 150 bps, with both measures impacted by tariffs, partially offset by benefits from volume and price.\n\n\n\nDiluted EPS was $0.98 versus $1.02, down $...